Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate.

@article{Fung1990ActiveSI,
  title={Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate.},
  author={Peter yee-shun Fung and Marcin Madej and R. Rao Koganty and Bryan Michael Longenecker},
  journal={Cancer research},
  year={1990},
  volume={50 14},
  pages={
          4308-14
        }
}
A synthetic tumor-associated glycoconjugate (S-TAG) "vaccine" formulation was developed for active specific immunotherapy of a murine mammary adenocarcinoma (TA3-Ha). An S-TAG composed of the Thomsen Freidenreich hapten coupled to a conventional carrier protein (keyhole limpet hemocyanin) and emulsified in Ribi adjuvant, when administered s.c. (in four doses at 3 to 6 days apart) into hosts bearing TA3-Ha tumors, provided 25% long-term survival. When administration of this synthetic… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 47 CITATIONS

A fully synthetic immunogen carrying a carcinoma-associated carbohydrate for active specific immunotherapy.

  • Cancer research
  • 1999
VIEW 5 EXCERPTS
CITES RESULTS, BACKGROUND & METHODS
HIGHLY INFLUENCED

O-Linked Glycosylation in the Mammary Gland: Changes that Occur During Malignancy

  • Journal of Mammary Gland Biology and Neoplasia
  • 2001
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED